Jezper / Shutterstock.com
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
1) Different patentability standards
In some countries it’s very difficult, if not impossible, to get claims that include ranges of sequence identity, warns Kamrin MacKnight, chief patent counsel at protein engineering company Codexis.
“We’re stuck with claims that cover only a specific sequence. That makes it much easier for competitors to design around our patents, as all they have to do is change one amino acid,” says MacKnight.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
IP portfolios, patentability, amino acid, US Supreme Court, biotech, DNA, IP counsel, European Patent Office, USPTO, IPRs, inventions, litigation